Mercury and autism: Accelerating evidence?

Neuroendocrinology Letters

Volumn 26, Issue 5, 2005, Pages 439-446

  Mutter, Joachim ^d   Naumann, Johannes ^d   Schneider, Rainer ^a   Walach, Harald ^a,b   Haley, Boyd ^c  

^a European Office   (Germany)

^b UNIVERSITY OF NORTHAMPTON   (United Kingdom)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Autism; Dental amalgam; Developmental disorders; Estrogen; Ethyl mercury; Glutathion; Mercury; Methylation; Neurotoxicity; Testosterone; Thimerosal

Indexed keywords

ALUMINUM HYDROXIDE; DENTAL ALLOY; ESTROGEN; GLUTATHIONE; IMMUNOGLOBULIN; LEAD; MECOBALAMIN; MERCURY; METHIONINE SYNTHASE; NEOMYCIN; OXYGEN; TESTOSTERONE; TETRAHYDROFOLIC ACID; THIOMERSAL; UNITHIOL;

ANTIOXIDANT ACTIVITY; ATTENTION; AUTISM; AUTOIMMUNITY; BLOOD LEVEL; BRAIN DEVELOPMENT; CHELATION THERAPY; COGNITIVE DEFECT; CORRELATION ANALYSIS; DETOXIFICATION; DEVELOPMENTAL DISORDER; DISEASE PREDISPOSITION; DRUG POTENTIATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; GLUTATHIONE METABOLISM; HEREDITY; HUMAN; HYPERBARIC OXYGEN; IN VITRO STUDY; INFLAMMATION; INFORMATION RETRIEVAL; LONG TERM EXPOSURE; MEDLINE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRENATAL EXPOSURE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TISSUE LEVEL; VACCINATION;

EID: 29544441534     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses 2001; 56: 462-71.
2. Bernard S, Enayati A, Roger H, Binstock T, Redwood L. The role of mercury in the pathogenesis of autism. Mol Psychiatry 2002; 7:S42-S43.
3. Blaxill MF. Study fails to establish diagnostic substitution as a factor in increased rate of autism. Pharmacotherapy 2004; 24: 12-13.
4. Blaxill MF. What's going on? The question of time trends in autism. Public Health Rep 2004; 119:536-51.
5. Costa LG, Aschner M, Vitalone A, Syversen T, Soldin OP. Developmental neuropathology of environmental agents. Annu Rev Pharmacol Toxicol 2004; 44:87-110.
6. Davidson PW, Myers GJ, Weiss B. Mercury exposure and child development outcomes. Pediatrics 2004; 113(4 Suppl):1023-29.
7. Mutter J, Naumann J, Sadaghiani C, Walach H, Drasch G. Amalgam studies: disregarding basic principles of mercury toxicity. Int J Hyg Environ Health 2004; 207:391-7.
8. Blaxill MF, Redwood L, Bernard S. Thimerosal and autism? A plausible hypothesis that should not be dismissed. Med Hypotheses 2004; 62:788-94.
9. California Department of Developmental Services: Autism spectrum disorders: Changes in the California caseload and update: 1999 through 2002. Sacramento, CA. California Health and Human Services Agency, (2003).
10. Burton D. Truth revealed: New scientific discoveries regarding mercury in medicine an autism. Opening statement before the U.S. House of Representatives. Subcommittee on human rights and wellness, Sept. 8 (2004). Available from: URL: http://reform.house.gov/WHR/Hearings/EventSingle.aspx?EventID=18156 [cited 2005, September 20].
11. Geier DA, Geier MR. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit. 2005; 11:CR160-70.
12. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001; 107:1147-54.
13. Deth RC. Truth revealed: New scientific discoveries regarding mercury in medicine and autism. Congressional Testimony before the U.S. House of Representatives. Subcommittee on human rights and wellness, Sept. 8. (2004). Available from: URL: http://reform.house.gov/WHR/Hearings/EventSingle.aspx?EventID=18156 [cited 2005, September 201.
14. Warkany, J., Hubbard, D.M.: Acrodynia and mercury. J Pediatr 1953; 42:365-86.
15. Bradstreet J. A case-control study of mercury burden in children with autistic Disorders and measles virus genomic RNA in cerebrospinal fluid in children with regressive autism. Immunization safety review: Vaccines and autism. Institute of Medicine, Febr. 9 (2004). Available from: URL: http://www.iom.edu/subpage.asp?id=18065 [cited 2005, September 20].
16. Mutter J, Naumann J, Walach H, Daschner FD. Amalgam: Eine Risikobewertung unter Berücksichtigung der neuen Literatur bis 2005. [Amalgam risk assessment with coverage of references up to 2005]. Gesundheitswesen 2005; 67:204-216.
17. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol 2003; 22:277-85.
18. Mutter J, Naumann J, Sadaghiani C, Walach H, Drasch G: Mercury and autism: Response to the letter of K. E. v. Mühlendahl [Int. J. Hyg. Environ. Health 208 (2005) 435]. Int J Hyg Environ Health 2005; 208:437-8.
19. Mortada WI, Sobh MA, EI-Defrawy MM, Farahat EF. Mercury in dental restoration: Is there a risk of nephrotoxicity? J Nephrol 2002; 15:171-6.
20. Fischer RD. Truth revealed: New scientific discoveries regarding mercury in medicine and autism. Congressional Testimony before the U.S. House of Representatives. Subcommittee on human rights and wellness, Sept. 8. (2004) Available from: URL: http://reform.house-gov/WHR/Hearings/EventSingle.aspx?EventID=18156 [cited 2005, September 20].
21. Geier DA, Geier MR. Autism and thimerosal-containing vaccines: Analysis of the vaccine adverse events reporting system (VAERS). Immunization safety review: Vaccines and autism. Institute of Medicine, Febr. 9, (2004). Available from: URL: http://www.iom.edu/subpage.asp?id=18065 [cited 2005, September 20].
22. Redwood, L. Truth revealed: New scientific discoveries regarding mercury in medicine and autism. Congressional Testimony before the U.S. House of Representatives. Subcommittee on human rights and wellness, Sept. 8, (2004). Available from: URL: http://reform.house.gov/WHR/Hearings/EventSingle.aspx?EventID=18156 [cited 2005, September 20].
23. Weldon D. Congressional speakers. Immunization safety review: Vaccines and autism. Institute of Medicine, Febr. 9.(2004). Available from: URL: http://www.iom.edu/subpage.asp?id=18065 [cited 2005, September 20].
24. Willman D. The National Institutes of Health: Public Servant or Private Marketer? Los Angeles Times 2004; Dec. 22.
25. Institute of Medicine (US). Immunization Safety Review: Vaccines and Autism. Washington, DC: National Acedemy Press, 2004.
26. Hu LW, Bernard J, Che. Neutron Activation analysis of Hair samples for the Identification of Autism. Transactions of the American Nuclear Society 2003; v89:681-2.
27. Grether J, Croen L, Theis C, Blaxill M, Haley B, Holmes A. Baby hair, mercury toxicity and autism. Int J Toxicol 2004; 23:275-6.
28. Muhlendahl KE. Commentary regarding the article by Mutter et al. "Amalgam studies: Disregarding basic principles of mercury toxicity" [Int. J. Hyg. Environ. Health 207 (2004) 391-397]. Int J Hyg Environ Health 2005; 208:435.
29. Fido A, Al-Saad S. Toxic trace elements in the hair of children with autism. Autism 2005; 9:290-8.
30. Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC: Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 2004; 9:358-70.
31. James SJ, Cutler P, Melnyk S et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004; 80:1611-17.
32. Bradstreet J, Geier DA, Kartzinel JJ, Adams J, Geier M. A case-control study of mercury burden in children with autistic spectrum disorders. J Am Phys Surg 2003; 8:76-9.
33. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J: Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002; 360:1737-41.
34. Stoiber T, Bonacker D, Bohm KJ, Bolt HM, Thier R, Degen GH, Unger E. Disturbed microtubule function and induction of micronuclei by chelate complexes of mercury(II). Mutat Res 2004; 563:97-106.
35. Thier R, Bonacker D, Stoiber T, Bohm KJ, Wang M, Unger E, Bolt, HM, Degen G. Interaction of metal salts with cytoskeletal motor protein systems. Toxicol Lett 2003; 140-141:75-81.
36. Leong CC, Syed NI, Lorscheider FL. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport 2001; 12:733-7.
37. Mutter J, Naumann J, Sadaghiani C, Schneider R, Walach H. Alzheimer Disease: Mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuro Endocrin Lett 2004; 25:275-83.
38. Baskin DS, Ngo H, Didenko VV. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol. Sci 2003; 74:361-68..
39. Humphrey ML, Cole MP, Pendergrass JC, Kiningham KK. Mitochondrial mediated thimerosal-induced apoptosis in a human neuroblastoma cell line (SK-N-SH). Neurotoxicology 2005; 26:407-16.
40. Westphal GA, Asgari S, Schulz TG, Bunger J, Muller M, Hallier E. Thimerosal induces micronuclei in the cytochalasin B block micronucleus test with human lymphocytes. Arch Toxicol 2003; 77:50-5.
41. Boris M, Goldblatt A, Galenko J, James SJ. Association of MTHFR Gene variants wit autism. Journal of American Physicans and Surgeons 2004; 9:106-8.
42. Magos L, Brown AW, Sparrow S et al. The comparative toxicology of ethyl- and methylmercury. Arch Toxicol 1985; 57:260-7.
43. Oskarsson A, Palminger Hallen I, Sundberg J, Petersson Grawe K. Risk assessment in relation to neonatal metal exposure. Analyst 1998; 123:19-23.
44. Harry GJ, Harris MW, Burka LT. Mercury concentrations in brain and kidney following ethylmercury, methylmercury and Thimerosal administration to neonatal mice. Toxicol Lett 2004; 154:183-9.
45. Colmann E, Halsey NA, Golman LR, Westphal G, Hallier E. Mercury in infants given vaccines containing thiomersal. Lancet 2003; 361:698-99.
46. Geier MR, Geier DA. Mercury in vaccines and potential conflicts of interest. Lancet 2004; 364:1217.
47. James SJ, Slikker W 3rd, Melnyk S, New E, Pogribna M, Jernigan S. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology 2005; 26:1-8.
48. Muller M, Westphal G, Vesper A, Bunger J, Hallier E. Inhibition of the human erythrocytic glutathione-S-transferase T1 (GST T1) by thimerosal. Int J Hyg Environ Health 2001; 203:479-81.
49. Olivieri G, Brack C, Muller-Spahn F, Stahelin HB, Herrmann M, Renard P, Brockhaus M, Hock C. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J. Neurochem 2000; 74:231-6.
50. Olivieri G, Novakovic M, Savaskan E, Meier F, Baysang G, Brockhaus M, Muller-Spahn F. The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxidative stress, neurotoxicity and beta-amyloid secretion. Neuroscience 2002; 113:849-55.
51. Vojdani A, Pangborn JB, Vojdani E, Cooper EL. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol 2003; 16:189-99.
52. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57:67-81.
53. Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry 2004; 9:833-45.
54. Hornig M. Truth revealed: New scientific discoveries regarding mercury in medicine an autism. Congressional Testimony before the U.S. House of Representatives. Subcommittee on human rights and wellness, Sept. 8, (2004). Available from: URL: http://reform.house.gov/WHR/Hearings/EventSingle.aspx?EventID=18156 [cited 2005, September 20].
55. Westphal GA, Schnuch A, Schulz TG, Reich K, Aberer W, Brasch J, Koch P, Wessbecher R, Szliska C, Bauer A, Hallier E. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int Arch Occup Environ Health 2000; 73:384-8.
56. Havarinasab S, Hultman P. Organic mercury compounds and autoimmunity. Autoimmun Rev. 2005; 4:270-5.
57. Havarinasab S, Haggqvist B, Bjorn E, Pollard KM, Hultman P. Immunosuppressive and autoimmune effects of thimerosal in mice. Toxicol Appl Pharmacol. 2005; 204:109-21.
58. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004; 63:838-42.
59. Haley B. Reduced levels of mercury in first baby haircuts of Autistic children. Immunization safety review: Vaccines and autism. Institute of Medicine, Febr. 9, (2004). Available from: URL:http://www.iom.edu/subpage.asp?id=18065 [cited 2005, September 20].
60. Geier MR, Geier DA. The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses 2005; 64:946-54.
61. Schubert J, Riley EJ, Tyler SA. Combined effects in toxicology - a rapid systematic testing procedure: cadmium, mercury, and lead. J Toxicol Environ Health 1978; 4:763-76.
62. Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med 2003; 228:660-64.
63. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil 2003; 6:97-102.
64. Geier MR, Geier DA. Thiomersal in childhood vaccines, neurodevelopment disorders, and heart disease in the United States. J Am Phys Surg 2003; 8:6-11.
65. Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit 2004; 10, PI33-9.
66. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT, Vaccine Safety Datalink Team. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003; 112:1039-48.
67. Olmsted D. The Age of Autism: Witness. The Washington Times; May 10, 2005. Available from URL: http://washingtontimes.com/upi-breaking/20050508-112601-3643r.htm [cited 2005; September 20].
68. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004; 114:584-91.
69. Madsen KM, Lauritsen MB, Pedersen CB et al. Thimerosal and the Occurrence of Autism: Negative Ecological Evidence From Danish Population-Based Data. Pediatrics 2003; 112:604-6.
70. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290:1763-66.
71. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003; 25:101-6.
72. Bernard S. Analysis of the Danish Autism Registry Database in Response to the Hviid et al Paper on Thimerosal in JAMA. (2003). Available from: URL: http://www.safeminds.org/research/docs/Hviid_et_alJAMA- SafeMindsAnalysis.pdf [cited 2005, September 20].
73. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 2001; 108:1155-61.
74. Madsen KM, Hviid A, Vestergaard M et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347:1477-82.
75. Carbone KM, Rubin SA, Pletnikov M. Borna disease virus (BDV)-induced model of autism: application to vaccine safety test design. Mol Psychiatry 2001; 7 (Suppl 2):S36-7.
76. Autism Research Institute: Treatment options for mercury/metal toxicity in autism and related developmental disabilities: Consensus paper. (2005). Available from URL: http://www.autismwebsite.com/ari/dan/mercurymetaldetox.htm [cited 2005; September 20].
77. Buttar RA. Autism Spectrum Disorders: An Update of Federal Government Initiatives and Revolutionary New Treatments of Neurodevelopmental Diseases. Congressional Testimony before the U.S. House of Representatives. Subcommittee on human rights and wellness, May 6 (2004). Available from: URL: http://reform.house.gov/WHR/Hearings/EventSingle.aspx?EventID=13567 [cited 2005, September 20].
78. Harch P. Autism Spectrum Disorders: An Update of Federal Government Initiatives and Revolutionary New Treatments of Neurodevelopmental Diseases. Congressional Testimony before the U.S. House of Representatives. Subcommittee on human rights and wellness, May, 6, (2004). Available from: URL: http://reform.house.gov/WHR/Hearings/EventSingle.aspx?EventID=13567 [cited 2005, September 20].
79. Pendergrass JC, Haley BE. Mercury-EDTA Complex Specifically Blocks brain-tubulin-GTP Interactions: Similarity to Observations in Alzheimer's Disease. In: Status Quo and Perspective (International Symposium Proceedings ed. Friberg LT and Schrauzer GN). Stuttgart-New York: Gerog Thieme Verlag; 1995. pp. 98-105.
80. Pendergrass JC, Haley BE, Vimy MJ, Winfield SA, Lorscheider FL. Mercury vapor inhalation inhibits Binding of GTP to tubulin in rat brain: Similarity to a molecular lesion in Alzehimer's Disease brain. Neurotoxicology 1997; 18:315-24.
81. Gasset AR, Itoi M, Ischii Y, Ramer RM. Teratogenicities of ophthalmic drugs. II/Teratogenicities and tissue accumulation of thimerosal. Arch Ophthalmol 1975; 93:52-5.
82. Rampersad GC, Suck G, Sakac D, Fahim S, Fop A, Denomme GA et al. Chemical compounds that target thioldisulfide groups on mononuclear phagocytes inhibit immune mediated phgocytosis of red blood cells. Transfusion 2005; 45:384-93.
83. Fagan DG, Pritchard JS, Clarkson TW, Greenwood MR. Organ mercury levels in infants with omphaloceles treated with organic mercurial antiseptic. Arch Dis Child 1977; 52:962-4.